NewsSource: EClinCloud

EClinCloud Partners with Tencent Health to Build an AI Capability System for Clinical Research

4 min readEClinCloud Editorial Team
2026年10月29日一临云与腾讯云战略合作签约仪式合影

By EClinCloud. Originally published on the EClinCloud WeChat official account on October 30, 2026.

2026年10月29日一临云与腾讯云战略合作签约仪式合影

On October 29, at the 2026 Tencent Global Digital Ecosystem Summit, EClinCloud and Tencent Health entered into a strategic partnership. The two parties will combine enterprise agent tools such as Tencent WorkBuddy with EClinCloud's integrated clinical intelligence cloud platform to jointly build an AI capability system for clinical research, helping pharmaceutical companies, CROs, and research institutions reduce repetitive document organization and content preparation and receive intelligent support within familiar workflows.

As a leading AI company in the clinical research industry, EClinCloud provides pharmaceutical companies and research institutions with technology products, data quality analysis, and other services through its integrated clinical intelligence cloud platform and endpoint assessment technology. EClinCloud developed its proprietary agent "Linxiaofu" in-house and has built a multi-role agent collaboration system around tasks such as data capture, clinical monitoring, medical review, and project reporting.

WorkBuddy is an all-scenario AI office agent launched by Tencent in March of this year. Since its launch, WorkBuddy has continuously refined its user experience and has become the AI office productivity agent with the largest user base and highest popularity in China. In June of this year, WorkBuddy officially launched its Enterprise Edition, which has already been broadly deployed across more than 50 industries, including healthcare.

In this partnership, tools such as WorkBuddy will be combined with EClinCloud's scenario-based products and delivery workflows and integrated with system products including eCOA, EDC, RTSM, CTMS, eTMF, and IRC, enabling study teams to use intelligent capabilities within existing workflows without separate complex deployment.

The two parties will also conduct joint R&D around clinical research needs, combining Tencent's large models, agent platform, and cloud computing capabilities with EClinCloud's proprietary agent "Linxiaofu" and multi-role agent collaboration system to enhance the agents' ability to understand and execute specialized tasks.

From drafting a study protocol to reviewing study data and preparing medical documents and reports, clinical research teams must both process specialized information and repeatedly organize materials and content. Through this partnership, tools such as WorkBuddy will target these time-consuming tasks by embedding intelligent assistance into stages such as study configuration, data management, and medical support, helping teams shorten preparation time and devote more focus to professional judgment and project progress.

As the jointly built capabilities are deployed, study teams will be able to invoke scenario-proven capabilities within familiar product interfaces and workflows without building their own AI team or undertaking separate complex deployments, and without having to figure out how to use AI from scratch. Related support will also extend from data capture to endpoint assessment, medical documentation, and regulatory submission preparation, maintaining continuous alignment with study workflows.

Qin Long, Founder and CEO of EClinCloud, said:

"What EClinCloud has done over the past few years is move the entire clinical research workflow online; what we will do next is integrate Tencent's general-purpose AI capabilities into clinical systems so that agents truly understand clinical work and workflows, and so that partners receive not just a piece of software, but a complete AI solution."

In the view of Yan Peng, Vice President of Tencent Cloud and Vice President of Tencent Health, bringing intelligence to clinical research requires combining technical capabilities with real-world research scenarios:

"We hope to combine Tencent's technical foundation in AI and cloud computing with EClinCloud's scenario-specific capabilities, enabling pharmaceutical companies, CROs, and research institutions to obtain trustworthy clinical evidence faster."

In the future, EClinCloud will continue to work with Tencent Health to advance joint R&D and product co-building, and to explore practical pathways for intelligent clinical research alongside industry partners, integrating the capabilities of tools such as WorkBuddy more naturally into study teams' daily work to support high-quality clinical research.

About EClinCloud

EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated clinical intelligence cloud platform and endpoint assessment technology, providing global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as services such as scale management, linguistic validation, rater training, and data quality analysis, to build efficient and accurate digital solutions. Relying on AI prediction models and an intelligent data platform, it dynamically evaluates and assists in improving the success rate of drug clinical trials, helping shorten drug/device R&D cycles to benefit patients.

EClinCloud original article footer image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.